Liver-Mediated Protection of Ischemic Myocardium
Sep 5, 2023
Sept. 9, 2012
Liver-Mediated Protection of Ischemic Myocardium
Shu Q Liu, Brandon J Tefft, Di Zhang, Derek Roberts, Yu H Wu
I'll just show you the overall story about this presentation.
So the model we used was a mouse, myocardial ischemia or myocardial infarction, induced
by a ligation of coronary artery for 30 minutes, then removed the ligation and induced reperfusion.
So here, this is the left ventricular injury here, and when that happens, the injured cells
in this part and leukocytes that migrate into the injury site will upregulate and release
cytokines.
One, for example, is IL-6, interleukin-6, and cytokines release into circulation and
through various mechanisms get to the liver, and the liver will respond to myocardial infarction.
One way the liver responds is to mobilize or liberate or release physically hepatocytes,
liver cells.
And the liver cells are liberated into circulation, and a fraction of liver cells will get to
the heart, get to the broken heart here, right here, and settle in the heart or hold
to the heart, the lesion of the heart, and what liver cells do in broken heart is, and
they upregulate and release some protective proteins.
These are secreted proteins, small proteins released to the extracellular space, and these
protective proteins will act on various signaling pathways in the injured myocardium and eventually
will reduce cell death and protect ischemic myocardium from death or injury.
So with that, next I would like to show you where the story started.
So myocardial ischemia, it is like this, this is a mouse heart, real heart, and this
piece here is the infarct, and one liver responds to myocardial infarction, and this is how
liver cells are physically mobilized.
You see, how to read this image here?
This was from a liver histological section.
The green color is a transgenically induced YFP, yellow colored protein, specifically
expressed in liver cells by using transgenic modulation method, and this part, the dark
area here is called the central vein.
So a liver consists of many working modules or lobules, and each module contains a central
vein, and these individual cells, there are two here and there are three there, these
are just released from the liver parenchyma, or tissue, into the circulation.
So the released liver cells will go into circulation, this is a blood sample, and
you collect a blood sample and a smear sample on a glass slide, and you can see leukocytes
this guy here, blue color is cell nuclei, nucleus here, and green color is liver cells,
because only liver cells express the yellow fluorescence protein.
So when liver cells got into blood circulation, so this cartoon shows the path of the liver
cells, where the liver cells go.
So here, this is the liver.
So this green block is a single liver cell, and liver cells released into the vein here
immediately will dump into the vena cava, the largest vein in mammals.
So liver cells can survive the blood flow in vena cava, and immediately move to the
right heart, right ventricle, sorry, right atrium, right ventricle, and liver cells can
survive the right ventricular flow, and they get into pulmonary artery right here, and
go through the pulmonary circulation.
So liver cells are happy in the pulmonary circulation, they can survive, and they next
move to the left atrium right here, and get into left ventricle.
So if you get blood samples from left ventricle, you can still see a lot of yellow colored
liver cells.
So remind you that in the whole body of the mouse, only liver cells express yellow fluorescence
protein, the yellow fluorescence protein expression was driven by albumin promoter.
Albumin is a protein expressed in the liver only, well mostly.
Some other cells may also express, but to a much lesser level.
So the liver cells will go with the arterial blood flow, getting into the aorta right here,
and a small fraction will get into pulmonary artery right here, into the heart.
So that's where liver cells in the broken heart came from.
So one thing I'd like to say is that once liver cells got into the arterial system,
they immediately, within a short time, they just disintegrated, because of arterial shear
flow.
Arterial circulation and shear stress is very large, so liver cells can, mobilized
liver cells can not just withstand the arterial shear stress, they would just break down very
rapidly.
So how do you tell that?
So you can take blood samples from everywhere, like from vena cava, and right ventricle,
left ventricle, and from peripheral artery.
If you, for example, take blood sample from femoral artery, so you will not see any liver
cells.
So in myocardial infarction, by the way, only myocardial infarction induces liver cell
mobilization.
Any healthy animals or any controlled sham operated animals, you don't see liver cells
in circulation.
So if fractional, malfractional liver cells will animate a broken heart, so this is a
histological section from a lesion of the heart, so right here, the left portion right
here is the core area of the myocardial infarction, and right here, on the right side, there are
a few bundles here, those bundles are surviving cardiomyocytes.
And these brown dots are liver cells.
So this is using immunohistochemistry to label liver cells by using anti-yellow fluorescent
protein antibodies.
So you see, each dot represents a liver cell, because only liver cells express the yellow
color protein.
So any cells in the heart do not express such protein.
So this is the entire path for liver cells, or the fate of liver cells after mobilization
from liver.
Next, we asked, the question we asked was, what the liver cells are doing in the heart?
So they are mobilized to the heart, they must do something.
The other question is, how the liver cells are mobilized.
So in this presentation, I would like to address these two questions.
First, we will start with how liver cells are mobilized.
Why myocardial infarction induces liver cell mobilization.
As I briefly mentioned, IL-6, the interleukin-6 expression, might be playing a role for liver
cell mobilization.
So this is where we started, and the first thing you do is test if IL-6 is upregulated.
So we collected liver heart specimen from the entryway site, and using immunoprecipitation
and immunoblotting analysis to test the IL-6 expression.
At different times, three, five, up to 30 days, we collected specimens from the heart
and the expression of interleukin-6 protein.
You can see that at three, five days post myocardial infarction, you can see a significant
increase in IL-6 level in the heart.
Similarly, you can test the IL-6 level in the blood in circulation, using ELISA and
actually IL-6 level was also upregulated in blood.
Next thing we did was try to find out what IL-6 did in myocardial infarction.
What we found was IL-6 activates leukocytes.
While IL-6 appears, was dumped into circulation and acts on leukocytes in circulatory system,
and activated leukocytes will go to the liver.
Sure, a fraction will go to the liver and are retained within the liver.
In healthy animals, this is a liver specimen.
The green color is a yellow fluorescent protein because only hepatocytes or liver cells express
this protein.
The blue dots are cell nuclei.
You can see in a healthy animal, or here is a sham operated animal, meaning you cut open
the chest wall and you do something on the heart, manipulate the coronary artery, but
you do not induce occlusion of the coronary artery.
In this case, you only see liver cells.
Sure, somewhere you will see blood vessels and bile ducts, but in animal mice with myocardial
infarction, in addition to the liver cells, green color, you will also see the red colored
leukocytes.
So, leukocytes were labeled with an antibody against a leukocyte marker.
It's called leukocyte common antigen.
It's a CD45.
So, the red color just indicates these are leukocytes.
So, that means that in myocardial infarction, leukocytes will migrate through the liver
capillary wall or endothelial cells and get into the parenchyma of the liver.
But when you knock out IL-6, just completely genetically remove IL-6 in the mouse, and
you don't see leukocytes retention within the liver post myocardial infarction.
But if you inject recombinant mouse IL-6 protein into the circulation of IL-6 and knock out
mice, leukocytes retention will appear.
So, this will suggest that IL-6 activates leukocytes, and leukocytes are retained within
the liver post myocardial infarction.
The next thing is we will ask what the leukocytes do in the liver.
So, they retain there, and they must do something.
And once they actually found that the leukocytes do is upregulate MMP2.
It proteinates.
It collagenates.
So, the target of MMP2 is collagen, and also basal lamina is moderate extracellular matrix.
So, these are images from RT-PCR.
Reverse transcriptase PCR.
Testing messenger expression of MMP2 can see mice with sham operation without myocardial
infarction.
You only see a minimal basal level expression of MMP2 from liver specimen.
However, in MI myocardial infarction, you can see upregulation of MMP2 messenger RNA
at 3, 5, 10 days.
So, this shows that myocardial infarction upregulate or induces upregulation of leukocyte
messenger RNA of MMP2.
Next thing we did was to test the MMP2 activity by using demography.
You just mix some gelatin, broken collagen molecules in a gel block to run electrophoresis
gel and see if the liver specimen or lysate will degrade gelatin.
If gelatin is degraded, you will see some white bands.
So, in sham-operated mice, you see only minimal basal level of activity of MMP2 or expression
that was very low.
However, in myocardial infarction at 3, 5, 10, 20, or 15 days, 20 days even, you can
see significantly increase in MMP2 level.
Meaning that in myocardial infarction, one leukocyte or retained within a liver leukocyte
will upregulate and release MMP2.
So, that's what this slide tells us about.
So, now it's liver cell mobilization again, but with a larger magnification.
The image is showing you the details here.
So, what MMP2 does is to just break down collagen anywhere here.
There are many red dots here.
Each red dot is a leukocyte, like here.
This is a large image from this plot here.
So, here you see these two liver cells were just mobilized and there you find at least
one or two leukocytes.
So, the red thing here is a leukocyte CD45 and anywhere you find a leukocyte here, like
here, there, there, this red block, the leukocyte will locally release collagenase, the enzyme.
Collagenase will break down locally collagen and basal lamina right here in the capillary.
Then one collagen and basal lamina are broken and degraded and liver cells just released,
mobilized.
So, here these three here, a cluster of liver cells.
You can also see a leukocyte there.
So, it seems that anywhere you have a retained leukocyte within a liver and the
liver cells in the neighborhood will be physically mobilized because release of MMP2.
So, next is this slide shows the appearance of liver cells within circulation.
This panel shows the liver cells directly oscillated from a liver.
You just use collagen, you inject collagenase into liver and mechanically dissociate liver
cells and I would like to show you that there are two cells mostly you will see in liver
specimens.
One is a green colored cell.
These are hepatocytes, which takes about 85% of the liver cell population.
And this green cell with the red circle here, this is an epithelial cell from a bioduct.
They're called bioduct epithelial cells.
The tube that conducts bile from liver.
And this slide was from a blood sample.
You can see that the blood sample from the vena cava.
Remember that only you get blood samples from vena cava, right ventricle and left ventricle.
You can see liver cells.
If you get blood samples from a peripheral artery, you will not see these liver cells
because they just break up.
And these look like hepatocytes with the green color.
It's a yellow fluorescent protein again.
So this is also a blood sample.
You can see three leukocytes.
These blue color, the cell dots are cell nuclei.
And this guy, it's a bioductular cell from the liver.
Green color shows a yellow fluorescent protein.
And red color shows an epithelial cell marker for a bioduct.
That's a CK cytokeratin-19.
This CK-19 is expressed in epithelial cells, but mostly in the liver at bioductular cells.
In blood sample, after myocardial infarction,
you will see about 1.8% of liver cells in vena cava blood sample.
1.8% is the peak right at five days after myocardial infarction.
But after five days, the circulating liver cell population just dropped.
So this is just a cytometry analysis showing you the population of liver cells in blood.
I will just skip that because of time.
Next is, if liver cells hold to or go to the broken heart or lesion of the heart,
this panel shows a section from a broken heart.
This is myocardial infarction core, and this is peripheral area.
You can see a few surviving cardiomyocytes.
This red block is right here.
This is a magnified.
The brown colored pieces are liver cells.
This is using immunohistochemical assay to label yellow fluorescence protein
because only liver cells express yellow fluorescence protein.
Cardiac cells did not express that.
In the heart, right here in this area,
we found about 4% of liver-derived cells in broken heart.
That's the maximum population.
At about five days post-myocardial infarction, after five days,
the population with dense liver cells dropped.
At this time, we just don't know what happened to the liver cells,
why they disappeared.
They might be dead, or they might transform into other cells,
but we have not got a chance to look at that issue at this time.
Next thing is we asked what the liver cells are doing in a broken heart.
One thing is to upregulate and release cardioprotective factors or proteins.
These proteins just reduce the level of myocardial injury or death.
The approach we used was DNA microarray analysis.
We just screened the whole mouse genome from the liver,
specimens from liver post-myocardial infarction at 1, 5, 10, up to 30 days.
What we found was there were about 600 genes in liver cells
upregulated in response to myocardial infarction.
About 300 liver genes were downregulated in response to myocardial infarction,
but we did not care much about the intracellular molecules.
What we did care about was the secreted protein genes
because only these secreted protein genes might be involved in myocardial protection
because the proteins are released and get a chance to get to the heart.
We found nine secreted protein genes that were upregulated.
These include AGP2, that's alpha-1 acid glycoprotein 2,
BMPER, that's BMP, bone morphogenetic protein binding endothelial cell regulator,
and CXCL13, that's chemokine 13, FGF21, fibroblast growth factor 21,
NRG4, neureguline 4, PRG4, proteoglycan 4,
SA1, serum amyloid A1 and A2, and PFF3, that's trifoil factor 3.
These are the nine secreted protein genes that were upregulated in the liver
in response to myocardial infarction.
You can see that the maximum level among these nine genes was about 80-fold increase,
80 times increase in mesogenic expression level.
That's quite high.
Minimum level is BMPER here is about six-fold increase.
That's quite high, quite a level of increase.
In terms of time, you can say for most protein genes here, secreted protein genes,
the peak was at about one day, like one day,
and some of them at about half day, like FGF21, others at 10 days.
Different times reflect different functions.
Some might be evolving cardioprotection early time,
others for myocardial regeneration later time, such as PFF3.
What are the functions of these proteins?
So far, none of these proteins was identified as myocardial protective proteins.
So what do we know?
We know about the functions of these proteins from literature is AGP2 is an inflammatory,
acute inflammatory protein involved in inflammation regulation, like we cut our skin.
In the infection, an AGP2 might be released from local cells and just mediate inflammation.
And this BMPER molecule just mediates the function of BMP4.
BMP4 is a molecule that regulates the formation of bone or heart.
And chemokine 13, it's a cytokine.
It regulates inflammation, inflammatory responses.
FGF21 regulates glucose level, just behaves like insulin,
but it's not insulin.
Can lower glucose, actually works for mice, rats, and cats, and humans.
But currently, FGF21 has been used to lower human glucose level for diabetes.
PRG4 is a factor regulating neuronal growth and development.
PRG4 is also a serum, blood-borne protein, regulates inflammation.
SA1 serum amyloid is also an acute inflammatory factor.
The function has not been identified.
But what do we know?
Amyloid A1, A2 are bad.
Just that they accumulate in organs and form amyloid.
Amyloid clusters and conjugates, aggregates.
And they just affect the normal function of the cells.
So PFF3 was originally identified from the intestine and the stomach.
The function of PFF3 is to produce a layer, protective layer for intestine.
And reduce the injury of protecting intestine from injury.
So now we found that all these molecules are upregulated in the liver in response to myocardial
infarction.
So the hypothesis from that was, well, these molecules might include cardio protective
factors.
In the following, I'm going to show you how to find cardio protective factors from
this population of secreted proteins upregulated in the liver.
So the screening method was the injection of recombinant protein.
Each of the recombinant proteins for the nine, well, actually we tested seven proteins.
Because amyloid A1, A2 are bad.
We did not test those.
Well, the hypothesis was, well, these two might not do anything good for the heart.
It can only be bad.
So we tested seven.
We inject a recombinant protein for a particular liver derived secreted protein into the circulation
immediately after myocardial infarction was induced in the mouse.
So this column shows left ventricular specimen slices.
And this is a mouse heart.
Right here, there's a white dot here.
That's this location where coronary artery location was.
And below that location point, from each heart, got three pieces, one immediately below the
location.
Second piece from the middle here.
Third piece from the apex area.
So each circle here is a slice from left ventricle.
So the color codes.
Red color shows good heart.
Well, intact, healthy, myocardium.
White color is bad, infarct.
So PBS means PBS phosphate buffer saline injection that's controlled.
And you induce myocardial infarction.
You inject PBS.
Then, well, at 24 hours post myocardial infarction, you just collect these specimens.
So you get that much of white color, bad tissue.
So bad area.
And this is a CXCL13.
You will get a higher, well, about the same level of myocardial infarction, bad tissue
as PBS.
PRG4 did not do anything good.
But the remaining five factors, when each is injected into the mouse circulation, you
can see a significant reduction in the white, bad area.
So that's the message from this slide.
So all five columns show each column represents the result from after, say, AGP injection
or bumper injection and so on.
So the last column shows results from a group, from an animal with injection of a combination
of all five protective factors.
You can see even more reduction in the bad area, infarction.
So this is just an analysis for the reduction for the protective effect.
In short, five proteins, each induced a significant reduction in myocardial infarction.
So therefore, that protein was selected as a protective factor for the heart.
Next thing we did was tested the protein level.
Protein expression of the five protective factors in the liver.
So this column shows the immunoglobulin analysis for all five factors, including beta-actin,
which was used as a control, loading control, just showing equal amount of protein was loaded.
You can see probably there's a slight increase in some of the protein, like bumper here and
FDF21, during the course, post myocardial infarction.
But in myocardial infarction, you can see that at half day one, three, five days, you
can see upregulation of the protein, the five protein in the liver in response to myocardial
infarction.
One point I like to point out is that a unique expression pattern for TFF3, TFF3 was high,
was higher at day three, and then dropped a bit at day five and come back, get higher,
much higher at day 10 and 20.
So there are two peaks for that.
Our guess was the first peak for TFF3 was early protection for the heart, and the later
peak was for some myocardial regeneration responses, but we have not looked into that
issue.
This simply shows the serum or blood level of these five proteins by using ELISA.
So the message here is for all the five cardioprotective proteins, you can see a transient increase
in the serum level from day one to about day 10.
Some from day one to day 10, some from day one to day five, like FDF21 was day one from
five, you can see a peak increase in FDF21 in serum.
Actually, in human patients with myocardial infarction, you can also see FDF21 increase.
But the FDF21 function or protect function has not been found in humans.
Next thing, what we did was, well, we like to know the long-term effect of these cardioprotective
factors.
So what we showed, we have seen was just a short-term, 24 hours protection.
That was just for screening purposes.
So now we're going to test, what about after, say, 20, 30 days post myocardial infarction?
Will the liver secreted proteins protect the heart?
One thing we like to do is, in myocardial infarction, you have to detect if the protein
you deliver can get to the heart.
You see, to cure a disease or protect cardiac injury, cardiomyocytes from injury, so you
have to know if this protein is present in the injury site.
To test that, we used a fluorescein conjugated FDF21 molecule.
And we get protein, get fluorescein, and mix up and use some chemical assay to link the
fluorescein fluorophore to the protein.
And inject the fluorescein protein to circulation.
And after one day, and remove a piece of the left ventricle here.
This is a left ventricle specimens.
We have seen that labeled by TTC reagent.
So red again is a good intact myocardium, and white is infarct.
You can see that the fluorescein FDF21 only ended up in the lesion, the broken heart.
But did not go through the capillary network, or go through capillary endothelial cells
in the intact myocardium.
So this is because the injury area, the permeability of endothelial cells increased.
Allow protein to diffuse from blood compartment into interstitial compartment.
This shows simply that any injected protein can end up in the lesion.
Next, we did was the long-term protective effect of the injection of the five liver
derived proteins at five, 10, 30 days.
So the assay here, the assay we used was orange, red, and brilliant blue.
Two color.
The red color, orange, red dye stains intact, healthy, good myocardium, and brilliant blue
stains collagen, simply stains fibrosis.
So the left column shows PBS control.
So each circle was from the heart.
This was from the middle of the left ventricle.
This part here, the same layer is right ventricle.
This circular part is left ventricle.
You can see that at five days, you get that much of fibrosis, scar tissue, the green color.
10 days, the blue color shows fibrosis or scar at 30 days.
Well, after you inject a combination of five liver derived protective proteins, I can
see that the blue colored fibrosis, fibrotic region was significantly reduced.
So this is just analysis showing you statistical significant reduction in myocardium function.
So the conclusion was that we can use a combination of the five liver derived secreted
proteins to reduce myocardium function.
So this has implications for clinical application.
So currently, we're developing some of the liver derived proteins for human applications.
One was TFF3, because TFF3 is the most effective single factor.
And also, TFF3 protects ischemic left ventricle from rupture.
For example, you use TFF3 knockout mines, you induce myocardium function.
Within five days, post myocardium function, about half or even more of the animals will
experience sudden left ventricle rupture.
The animals die within five minutes, because the heart is broken, rupture, because of infarction.
So, if TFF3 is not there, knockout, no TFF3 expressed in this animal, and the left ventricle
cannot just hold the pressure.
But, in a wild type animal, TFF3 is there, and the rupture rate for the left ventricle,
post myocardium function, dropped below 10%.
You see, there's a huge difference.
So, that simply means that TFF3 protects the left ventricle from rupture.
So, right now, we're trying to understand the mechanism behind that.
Could be anything inside the cell, or it could be something extracellular matrix.
So, TFF3 will promote the mechanical strength of the broken heart.
The next thing we did was, after cardiography, to test the contractility of the heart.
But, because of time, I would like to skip this.
Also, we tested the left ventricular DPDT.
It's a parameter used to test the left ventricular contractility.
So, we'll skip this, also, because of time.
Another thing I'd like to talk about is the action of the naturally expressed
liver-derived secreted proteins in animals, in the mouse.
So, the question is, do these liver proteins protect heart in wild type animals?
So, a common approach to test such a problem is loss-of-function test, meaning that you have to remove.
If you like to test the function of a factor, or protein, you have to remove that factor, or that protein.
That's called loss-of-function.
So, here we have five cardioprotect proteins here.
We have to remove five.
Gene knockout is a good model, but knocking out five, it's very difficult.
I haven't heard anyone, any lab, can do that.
Probably most of it can knock out.
It's just the two, double knockout, would be very challenging.
But here, five is very difficult.
We didn't even try that.
So, how you knock out or remove, partially or completely, of these five factors.
So, we took the approach, SRNA, small interferon RNA approach.
So, you simply dump five, a combination of five, SRNA regions into circulation.
And so, the animals, probably including humans, have a feature.
That is, any SRNA you inject into circulation, the liver will take up at least 80% of it.
After a few minutes.
That's great, because we try to knock down or remove the liver proteins,
and the liver cells will take up most of the SRNA molecules.
So, SRNA will get to the liver and actually significantly knock down
the expression of all the five protein genes.
Look at here, say this is AGP2.
Pb-assay injection, you have that much expression in AGP2 at, say,
three days after SRNA injection, but one day after myocardial infarction.
So, we inject the SRNA three days prior to induction of myocardial infarction.
And then you assay the protein levels.
So, they use a controlled SRNA, meaning that that SRNA does not reduce messenger RNA level
for any known genes.
And the specific SRNA is just AGP2 specific.
So, SRNA is very specific.
Each SRNA can only knock down the expression of messenger RNA, target messenger RNA.
You can say SRNA treatment probably knocked down about 80% of the protein level.
That really worked.
Next thing we did was, well, what happened after SRNA immediately knocked down?
If you can still see, well, you can see protective factor,
protective effect where you increase or decrease cardiac protection.
It turns out that SRNA knockdown induced a re-increase in myocardial infarction,
meaning that if you remove a protective factor,
so the heart is no longer protected by that factor.
So, therefore, myocardial re-injury or infarction re-increased.
So, these are images from left ventricles, broken left ventricles,
passed by TTC reagent.
So, the message here from this slide was that knockdown where you partially remove
these five proteins from the system, from the animal,
and the myocardial infarction level will increase.
That will prove partially, at least, that these liver-derived five secreted proteins
do protect heart from injury or death.
So, we also tested the left ventricular DPDT and the actual cardiography.
We'll just skip that.
It's for SRNA treatment.
Well, in the remaining couple minutes, I will just briefly mention about the mechanism.
How these liver-derived proteins act to protect the heart.
I mean, you just got a bunch of small molecules,
so these molecules can get to the broken heart and how they work.
So, this shows the pathway.
Major molecules that really the liver protein get to the inside of the heart is giving cardiomyocytes
to eventually promote cardiomyocytes to life.
For example, FDF21 first will act on FDF receptor 1.
Actually, there are four types of FDF21 receptors.
And cardiomyocytes in the mouse express receptor 1 and 3, like shown here.
So, here is receptor 1 cardiomyocyte from sham control animals and also from animals
with myocardial infarction, 1, 3, 5, 10 days.
3, receptor 3 is also expressed in cardiomyocytes in the mouse,
but 2 and 4 are not expressed, just in nature.
So, FDF21 turns out to act on receptor 1.
The receptor 1 activates an intracellular molecule called PR3K.
It's just a kinase.
K stands for kinase that acts to add a phosphate group to a phospholipid molecule in cell membrane.
And PR3K acts on a phosphate lipid molecule called PRP2 and turns that into PRP3,
meaning one more phosphate group added to this phospholipid group molecule.
And PRP3 will activate another molecule called AKT1.
It's also a kinase.
So, a kinase will act on a downstream molecule called BAD.
That's Bcl-2-associated death promoter.
It's, well, the name doesn't mean anything, but that thing causes cell death.
But if AKT1 is activated, AKT1 induces phosphorylation, adding a phosphate group to BAD molecule.
That will shut down the activity of BAD, will reduce cell death.
So that's the mechanism.
So in the end, BAD is phosphorylated with a phosphate group, and it can no longer work.
Therefore, it can no longer induce cell death under ischemic condition.
Therefore, ischemic cardiomyocytes will survive.
So that's how FDF21 works.
At this time, we're only working on FDF21 and TFF3.
We don't know how the remaining three factors work.
So the whole message here is that whatever molecule is protected and cannot save dead cardiomyocytes.
But a heart, for a broken heart here, you see the white area, the core area, the center of the white area.
Well, that contains the dead cells.
I mean, nothing can save those cells.
God cannot save those cells because they are dead for good.
And the protect factors only act on the peripheral area here,
act on injured cardiomyocytes, but not yet dead.
So if this signaling pathway is activated,
so the injured, not yet dead cells, can be saved, can be rescued.
So that's the idea.
Well, with that, I'd like to get a conclusion part.
Well, many conclusions we can make based on the information we just talked about.
I'd just like to see one thing.
That is, the liver has been evolved as a organ contributing to myocardial protection.
There are two ways for the protective action.
One is to mobilize cells, home cells to broken heart.
And the broken heart liver cells will release, upregulate and release secretory proteins.
So these proteins will rescue injured cardiomyocytes from death.
Well, I'd like to thank you for being here.
And I'll stop here and be glad to answer some questions.
All right, so the questions.
Yeah, that's really a question that got to the point.
We spent two years.
We could not answer that question.
Well, both liver cell homing to the heart and direct liver cell secretion of these proteins
will work in terms of myocardial protection.
But which one is more important, I don't know.
We have to, as you just said, we have to block one and look at the other.
The problem for that, the head question is, we just don't have a method to block
either of these two events.
Would be really nice if you can help me to find a method to block liver cell mobilization.
That would be great.
We just cannot find any way to block liver cell mobilization.
It's there.
It's nature.
You have a broken heart there.
Heart is short of protective mechanisms, just like brain.
Any of these important vital organs, they have very limited capability or capacity of
protection.
We just don't understand why.
And nature selects a liver or some other organs.
Other organs might also be involved.
We just did not get a chance to look at.
And nature selects a liver to be responsible for myocardial protection if the heart is
broken.
Now you try to block that.
You just cannot block liver cell mobilization.
You cannot block liver cell secretion of this protein either.
You can say, well, you can use the sRNA.
We've used that.
But you cannot completely block.
The sRNA can only block knockdown about 80%.
There's still 20% protein out there.
This 20% protein might also play a major role.
And well, for liver cell mobilization, well, you say, well, that's a physical event.
You just can't do something physically to block it.
You can't just knock.
Because anything you're sticking into circulation will cause thrombosis.
And the blood vessel will be completely occluded within hours or days.
You see, why don't you just remove the liver?
Well, you just cannot.
Anymore without it, it wouldn't be.
You can't remove the liver.
If you remove the liver, it's not related to something.
No.
Well, liver cells will not home to any healthy tissue.
I don't know why.
Because to get to any peripheral organ, liver cell must go through arterial system.
Well, liver cell will be sheared to pieces.
That we have tested.
Because you can't collect liver cells by using collagenase trait amount.
And you drop that into a flow chamber system.
And you just gradually increase the flow rate, the shear stress, up to a critical level.
And all the liver cells just sheared into pieces.
Slightly below the arterial shear stress level, liver cells just cannot survive.
Thank you very much for a fascinating talk.
Sure.
Really great.
Thank you.

